Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study
Therapeutic Advances in Medical Oncology
Published online on May 23, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Although gemcitabine plus nab-paclitaxel (Gem-NabP), modified FOLFIRINOX (mFOLFIRINOX), and NALIRIFOX are all recommended by current clinical guidelines as first-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC), ...
Background:Although gemcitabine plus nab-paclitaxel (Gem-NabP), modified FOLFIRINOX (mFOLFIRINOX), and NALIRIFOX are all recommended by current clinical guidelines as first-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC), ...